NEAT1 Negatively Regulates Cell Proliferation and Migration of Neuroblastoma Cells by MiR-183-5p/FOXP1 Via the ERK/AKT Pathway
Overview
General Surgery
Affiliations
Neuroblastoma, a malignant tumor of the sympathetic nervous system, is an aggressive extracranial tumor in childhood. Long noncoding RNAs (lncRNAs) have been discovered to play a key role in the eukaryotic regulatory gene network and be involved in a wide variety of biological processes. We observed that the expression of lncRNA nuclear-enriched abundant transcript-1 (NEAT1) was significantly decreased in human neuroblastoma tissues and cell lines, compared with the normal. We observed cell proliferation, migration, and invasion with Cell Counting Kit-8 assay, colony formation assay, and Transwell assay to investigate the effects of NEAT1, miR-183-5p, or FOXP1 on neuroblastoma cells. And we also used StarBase and luciferase reporter gene assay to predict and confirm the interaction of NEAT1, miR-183-5p, and FOXP1 in neuroblastoma cells. First, overexpression of NEAT1 suppressed cell proliferation and played a key role in cell migration and invasion. In addition, NEAT1 was demonstrated to directly interact with miR-183-5p and exerted its antioncogenic role in neuroblastoma by negatively regulating miR-183-5p expression. miR-183-5p suppressed the expression of FOXP1 and regulated cell proliferation and migration by directly targeting FOXP1 mRNA 3'-untranslated region. Moreover, FOXP1 antagonized the effect of miR-183-5p on the phosphorylation of extracellular-regulated kinase/protein kinase B (ERK/AKT), while FOXP1 siRNA increased the reduced phosphorylation of ERK/AKT caused by miR-183-5p inhibitor in neuroblastoma cells. Taken together, these data showed that NEAT1 negatively regulated cell proliferation and migration of neuroblastoma by the miR-183-5p/FOXP1 axis via suppression of the ERK/AKT pathway. Our findings may provide a new target for the study of pathogenesis and treatment of neuroblastoma.
Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.
Vercouillie N, Ren Z, Terras E, Lammens T Int J Mol Sci. 2024; 25(11).
PMID: 38891878 PMC: 11171840. DOI: 10.3390/ijms25115690.
MicroRNA-183 cluster: a promising biomarker and therapeutic target in gastrointestinal malignancies.
Zheng Y, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zhao R Am J Cancer Res. 2024; 13(12):6147-6175.
PMID: 38187051 PMC: 10767355.
lncRNA LINC00960 promotes apoptosis by sponging ubiquitin ligase Nrdp1-targeting miR-183-5p.
Yang H, Jiang T, Fan L, Qiu X Acta Biochim Biophys Sin (Shanghai). 2023; 55(1):91-102.
PMID: 36722261 PMC: 10157604. DOI: 10.3724/abbs.2023005.
Zhang C, Gu H, Liu D, Tong F, Wei H, Zhou D Mol Cell Biochem. 2022; 477(11):2627-2641.
PMID: 35598218 DOI: 10.1007/s11010-022-04465-6.
The role of long non-coding RNA FGD5-AS1 in cancer.
He N, Xiang L, Chen L, Tong H, Wang K, Zhao J Bioengineered. 2022; 13(4):11026-11041.
PMID: 35475392 PMC: 9208527. DOI: 10.1080/21655979.2022.2067292.